Reata Pharmaceuticals recently announced the recruitment of the first patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in their Phase 2 LARIAT clinical trial evaluating the efficacy, safety, and tolerability of experimental therapy bardoxolone methyl in the treatment of patients with pulmonary hypertension (PH). The recent enrollment is part of…
News
A new study reported that patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) often experience lung function decline, which furthers disease progression. The study, titled “Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis,” was published in the journal…
In a new study entitled “The matrix protein Fibulin-5 lies at the interface of tissue stiffness and inflammation in fibrosis,” an international team of scientists discovered a new protein – Fibulin-5 – involved in skin fibrosis, and with potential therapeutic implications in fibrosis in other organs, including…
Spherix Global Insights, GmbH, a business intelligence and market research company based on Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled “…
In a new study, clinicians propose a new treatment protocol without immunosuppressants or high-dose steroids to manage and treat acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF). The study, titled “Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach,” was published in the journal…
Boehringer Ingelheim recently announced the enrollment of the first patient in its Phase 3 clinical trial, called SENSCIS (Safety and Efficacy of Nintedanib in Systemic Sclerosis), evaluating the safety and efficacy of the company’s product nintedanib (OFEV) in patients with systemic sclerosis and interstitial lung disease. Systemic sclerosis is a…
Throughout 2015, Pulmonary Fibrosis News reported on studies in the field of pulmonary fibrosis care, treatment and disease management, as well as on events related to the condition. As the year comes to an end, here are the 10 articles most widely read by Pulmonary Fibrosis News readers, patients, caregivers and their…
DS Biopharma, headquartered in Dublin, Ireland, and focused on therapies for inflammatory and fibrotic skin and pulmonary disorders, recently announced that a Phase 1 clinical trial evaluating safety and dosing levels for its drug candidate DS102 (15-HEPE) has been successfully completed. DS102 is an oral bioactive lipid drug developed as…
A potentially important new study, published in the Journal of Biological Chemistry, identified fibroblast activation protein (FAP) as a crucial factor in collagen fragment clearance in the lungs. Clearing collagen fragments is a key step in reducing tissue scarring and restoring lung function following injury, making FAP an interesting target…
The University of Cincinnati (UC) Medical Center is among the 19 medical centers recently invited after careful review to become part of the Pulmonary Fibrosis Foundation (PFF) Care Center Network. The network now comprises 40 centers across 26 U.S. states with established expertise in the treatment of pulmonary fibrosis…
